ArticlePharmaceutical research2012
Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- Update on the Association of CD44 Expression with Esophageal Squamous Cell Carcinoma Invasion.Reports of biochemistry & molecular biology · 2025Article
- Photosensitizers-Loaded Nanocarriers for Enhancement of Photodynamic Therapy in Melanoma Treatment.Pharmaceutics · 2023Review
- Recent developments in natural biopolymer based drug delivery systems.RSC advances · 2023Review
- Controlled Drug Release from Nanoengineered Polysaccharides.Pharmaceutics · 2023Review
- Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer.Materials today. Bio · 2022Article
- Possible contribution of sialic acid to the enhanced tumor targeting efficiency of nanoparticles engineered with doxorubicin.Scientific reports · 2020Article
- Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor.Drug delivery · 2018Article
- Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors.Drug delivery and translational research · 2018Article
- Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles.Journal of cellular and molecular medicine · 2017Review
- Poly((D,L)lactic-glycolic)acid-star glucose nanoparticles for glucose transporter and hypoglycemia-mediated tumor targeting.International journal of nanomedicine · 2017Article
- Nanoparticles and nanofibers for topical drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Near infrared fluorescent nanoparticles based on hyaluronic acid: Self-assembly, optical properties, and cell interaction.Acta biomaterialia · 2016Article
- Article
- In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: insights and challenges in targeted cancer chemotherapies.International journal of environmental research and public health · 2014Article
- Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells.Pharmaceutical research · 2014Article
- The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles.International journal of nanomedicine · 2014Article
- Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery.International journal of nanomedicine · 2014Article
- Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.Molecular cancer therapeutics · 2013Article
- Polysaccharide-based micelles for drug delivery.Pharmaceutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyaluronic acid-ceramide (HACE)-based nanoparticles (NPs) were developed for the targeted delivery of doxorubicin (DOX), and their antitumor efficacy for melanoma was evaluated.
methodsDOX-loaded HACE-based self-assembled NPs were prepared and their physicochemical properties were characterized. The in vitro cytotoxicity of HACE was measured using an MTS-based assay. The cellular uptake efficiency of DOX into mouse melanoma B16F10 cells was assessed by confocal laser scanning microscopy and flow cytometry. Tumor growth and body weight were monitored after the intratumoral and intravenous injection of DOX-loaded NPs into a B16F10 tumor-bearing mouse model.
resultsDOX-loaded NPs, with a mean diameter of ~110 nm, a narrow size distribution, and high drug entrapment efficiency, were prepared. A sustained DOX release pattern was shown, and drug release was enhanced at pH 5.5 compared with pH 7.4. The cytotoxicity of HACE to B16F10 cells was negligible. It was assumed that DOX was taken up into the B16F10 cells through receptor-mediated endocytosis. A significant inhibitory effect was observed on tumor growth, without any serious changes in body weight, after the injection of DOX-loaded NPs into the B16F10 tumor-bearing mouse model.
conclusionsDOX-loaded HACE-based NPs were successfully developed and their antitumor efficacy against B16F10 tumors was demonstrated.
Indexed as
Identifiers
22886625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.